Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?

Eur Respir J. 2008 Apr;31(4):904-5. doi: 10.1183/09031936.00159807.

Authors

G B Migliori, C Lange, E Girardi, R Centis, G Besozzi, K Kliiman, L R Codecasa, A Spanevello, D M Cirillo; SMIRA/TBNET Study Group

Collaborators

SMIRA/TBNET Study Group:
J Ortmann, D Kirsten, A Gori, A Matteelli, S De Lorenzo, P Troupioti, G De Iaco, G Gualano, P De Mori, L Fattorini, E Iona, G Ferrara, G Sotgiu, M Danilovits, V Hollo, A Mariandyshev, O Toungoussova

PMID: 18378786
DOI: 10.1183/09031936.00159807

No abstract available

Publication types

Comment
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Anti-Bacterial Agents / pharmacology
Anti-Bacterial Agents / therapeutic use*
Estonia / epidemiology
Fluoroquinolones / pharmacology
Fluoroquinolones / therapeutic use*
Germany / epidemiology
Humans
Italy / epidemiology
Risk Factors
Russia / epidemiology
Tuberculosis, Multidrug-Resistant / drug therapy*
Tuberculosis, Multidrug-Resistant / mortality

Substances

Anti-Bacterial Agents
Fluoroquinolones